基因重组和尿卵泡刺激素在控制性超促排卵中的疗效观察

目的评估基因重组卵泡刺激素（rFSH）和尿卵泡刺激素（uFSH）在体外受精-胚胎移植（IVF—ET）和卵胞浆内单精子注射（ICSI）促排卵中的疗效。方法244例接受IVF和ICSI的不育患者,分为rFSH组103例、uFSH组141例,两组均采用黄体期长方案超促排卵。卵泡监测、取卵、IVF—ET按本中心常规进行。观察用药时间、剂量、费用,获卵数、卵裂率、优胚率、妊娠率及重度卵巢过度刺激综合征（OHSS）发生率等。结果rFSH组与uFSH组比较,使用FSH安瓿数显著减少（P〈0．05）,但费用比uFSH高（P〈0．05）,人绒毛膜促性腺激素（hCG）日雌二醇（E2）rFSH较uFSH高,但无显著差异。两组在获卵数、受精率、卵裂率、优胚率、胚胎种植率、临床妊娠率、流产和OHSS发生率无显著差异（P〉0．05）。结论uFSH和rFSH促排卵治疗同样有效、安全。     

不同类型卵泡刺激素在IVF/ICSI助孕人群中的疗效分析

目的 分析3种不同类型卵泡刺激素(FSH)在IVF/ICSI助孕人群中的治疗效果.方法 回顾性分析2018年1月至2020年7月就诊于我中心行首次IVF/ICSI助孕的2 456个周期的临床资料.根据FSH类型分为三组:进口重组FSH组(进口 rFSH组,n=1 445)、国产重组FSH组(国产rFSH组,n=455)...     

控制性超排卵与子宫内膜容受性

<正>控制性超排卵(COH)又称控制性卵巢刺激(COS),指以药物的手段在可控制的范围内诱发多卵泡的发育和成熟,其应用的对象本身多有正常的排卵功能,它是决定体外受精一胚胎移植(IVF-ET)成功与否的重要环节。子宫内膜容受性即子宫内膜接受胚胎的能力,子宫内膜间质腺体发生改变以允许胚胎定位、黏附、侵入接受的状态。子宫内膜允许     

辅助生育技术中的超排卵方案

控制性超排卵 (COH)是辅助生育技术 (ART)的关键 ,良好的COH方案 ,可获得同步发育的多个卵泡 ,高质量的成熟卵母细胞 ,从而提高受精率和妊娠率。由于超排卵反应存在个体差异 ,选择正确的促超排卵方案有助于提高ART的安全性及成功率。目前已经发展了大量个体化的超排卵方案 ,其中最主要的是基于促性腺激素的方案。     

低剂量长效GnRH-a在控制性超排卵方案中的临床应用

目的比较短效促性腺激素释放激素激动剂(GnRH-a)和低剂量GnRH-a长效制剂在控制性超排卵长方案中的应用效果,探讨低剂量长效GnRH-a在控制性超排卵中的应用价值。方法回顾性分析284个卵巢储备功能正常的长方案促排卵周期,其中低剂量长效组134个周期,短效GnRH-a组150个周期。对两组间垂体降调节效果、促性腺激素(Gn)使用剂量、时间、促排卵治疗中性激素的水平及IVF-ET结局进行比较。结果低剂量长效组降调节后血清黄体生成素(LH)水平[(0.95±1.58)U/L]、HCG日LH水平[(1.58±2.21)U/L]、HCG日雌二醇(E2)水平[(11 649.78±2 137.92)pmol/L]较短效组均低[分别为(1.25±1.58)U/L、(2.72±2.08)U/L)和(14 698.23±2 380.35)pmol/L],差异均有统计学意义(P0.05);Gn总量[(34.06±8.12)支]和Gn天数[(10.43±1.25)d]较短效组[分别为(27.91±7.54)支和(9.43±1.01)d]明显升高,差异均有统计学意义(P0.05)。两组获卵数[(10.96±2.01)vs.(11.28±2.08)枚]、MII卵数[(9.97±1.25)vs.(10.56±1.78)枚]、优胚数[(4.31±1.02)vs.(4.81±1.54)枚]、可利用胚胎率(64.81%vs.59.81%)、胚胎着床率(38.46%vs.35.34%)、临床妊娠率(55.05%vs.49.22%)、持续妊娠率(53.21%vs.47.66%)、周期取消率(2.24%vs.2.00%)以及重度卵巢过度刺激综合症(OHSS)发生率(0%vs.1.33%)等指标比较,均无统计学差异(P0.05)。结论在控制性超排卵中,低剂量长效GnRH-a单剂量可达到与短效促性腺激素释放激素激动剂相同程度的垂体降调节状态,临床结局满意。     

高纯度尿源卵泡刺激素在体外受精-胚胎移植周期应用的有效性研究

目的 探讨国产高纯度尿卵泡刺激素（丽申宝）在体外受精-胚胎移植（IVF-ET）周期应用的临床结局.方法 对2008年3月至2009年12月在本中心进行IVF-ET治疗,并完成胚胎移植的279例患者307个控制性超排卵（COH）周期临床资料进行回顾性分析.按COH中使用的不同促性腺激素（Gn）,患者分为果纳芬组（166例、183个周期）和丽申宝组（113 例、124个周期）,比较两组在用药时间、用药剂量、药品费、获卵数、临床妊娠率、中重度卵巢过度刺激综合征（OHSS） 发生率、妊娠结局及围生儿结局的差异.结果 两组用药时间、用药剂量、获卵数、成熟卵数、优质胚胎率及OHSS发生率均无显著差异;两组丽申宝组临床妊娠率（41.1%）、种植率（25.1%）、流产率（11.8%）、多胎率（33.3%）及抱子回家率（33.9%）与果纳芬组（分别为50.8%、31.4%、18.3%、32.3%、36.1%）相比亦无显著性差异;出生婴儿的胎龄、出生体重及出生缺陷均无显著性差异;而药品费用丽申宝组（5,092.68±1,388.98）明显低于果纳芬组（8,226±2,716.33）,有显著性差异（P〈0.05）.结论 丽申宝具有与果纳芬相同的促排卵效应和临床结局,但药品费显著低于果纳芬.     

控制性超排卵对子宫内膜容受性的影响及干预措施

正常子宫内膜仅在一个极短的关键时期允许胚胎着床,称为“植入窗”或“种植窗”[1].种植窗期,在体内多种激素特别是卵巢激素调控下,子宫内膜的形态学超微结构、特定基因表达、蛋白分泌等方面都发生时空特异性的系列改变,使子宫内膜的容受性达到最佳状态,以利于胚胎的定位、粘附和着床.控制性超促排卵(COH)改善和推动了辅助生殖技术的发展,该过程中,通过促排卵药的使用可以获得较多枚卵子,但是,这些药物有可能会影响人体多种内源性激素的分泌和平衡,使雌、孕激素异常分泌,干扰种植窗内膜的形态、功能,从而影响子宫内膜容受性,进而影响胚胎的着床,降低妊娠率[2,3].     

尿卵泡刺激素和基因重组卵泡刺激素在体外受精-胚胎移植临床疗效及安全性的比较

目的 比较国产尿卵泡刺激素（uFSH）和基因重组卵泡刺激素（rFSH）在体外受精-胚胎移植（IVF-ET）/卵胞浆内单精子显微注射（ICSI）中控制性超排卵（COH）的临床疗效及安全性.方法 293例行IVF-ET/ ICSI助孕的不育患者按不同用药分为uFSH组（96例）和rFSH组（197例）,比较两组促性腺激素（Gn）用量、Gn天数、费用、人绒毛膜促性腺激素（hCG）注射日雌二醇（E2）水平、取卵数、优胚数、冷冻数、受精率、妊娠率、流产率及卵巢过度刺激综合征（OHSS）发生率.结果 uFSH组患者的Gn用量（27.49±7.79）支显著多于rFSH组（25.50±7.84）支,但费用uFSH组（4,110.21±1,164.88）元显著少于rFSH组（7,839.22±2,480.75）元（P＜0.05）;两组患者Gn天数、hCG注射日E2水平、取卵数、优胚数、冷冻数、受精率、妊娠率、流产率及OHSS发生率均无显著性差异（P＞0.05）.结论 uFSH与rFSH相比,对IVF-ET/ICSI促排卵结局无明显影响,同样安全有效,且uFSH存在明显的价格优势. A comparison of clinical efficacy and safety between urinary follicle-stimulating hormone and recombinant follicle-stimulating hormone in IVF/ICSI treatment XIANG Yun-gai TAN Li ZHAO Dong-mei MA Li-ying HUANG Yu-rong XIAO Bing LI Qian     

两种促卵泡生长激素在辅助生殖治疗效果的比较

辅助生殖治疗中选择一种理想的制剂进行促超排卵，可明显提高妊娠率。本研究对我院生殖中心接受体外受精(IVF)和卵胞浆内单精子注射(ICSI)的患者，分别采用重组卵泡刺激素(rFSH)和高纯度尿卵泡刺激素(uFSH HP)促排卵，比较二者的治疗效果。     

高纯度尿源性FSH在不同年龄患者控制性超促排卵中的应用

目的研究国产高纯度尿源性FSH(HP-FSH,丽申宝)在不同年龄卵巢储备正常患者控制性超促排卵(COH)中的应用效果。方法回顾性分析我中心2011年1月1日至2013年12月31日使用国产HP-FSH或基因重组FSH(r-FSH,果纳芬)进行COH并接受体外受精/卵胞浆内单精子注射(IVF/ICSI)治疗的1 217例不孕症患者的临床资料。根据FSH启动日所用FSH种类分为HP-FSH组和r-FSH组,每组根据患者年龄再分为30岁、30~36岁及≥37岁3个亚组。采用独立样本t检验比较各年龄亚组间患者Gn天数、FSH总量、获卵数、每卵FSH量,采用χ2检验比较各亚组间MⅡ卵率、正常受精率、优质胚胎率、临床妊娠率及流产率。结果(1)3个年龄亚组中,HP-FSH方案组的FSH用量均显著高于r-FSH组(P0.05);在30~36岁组及≥37岁组,HP-FSH方案组的Gn天数显著长于r-FSH组(P0.05);在30岁组及30~36岁组,HP-FSH方案组的获卵数均显著少于r-FSH组(P0.05);3个年龄亚组中,HP-FSH方案组的每卵FSH量均高于r-FSH组,但仅在30岁组有统计学差异(P0.05)。(2)两种用药方案的MⅡ卵率、优质胚胎率及周期冷冻率在各年龄亚组间比较均无统计学差异(P0.05),仅在30~36岁组中,HP-FSH方案组的2PN率显著高于r-FSH组(P0.05)。(3)两种用药方案的临床妊娠率与流产率在各年龄亚组间比较均无统计学差异(P0.05)。结论对于不同年龄卵巢储备功能正常的患者,国产HP-FSH均能获得与r-FSH相似的辅助生育治疗结局,临床用药可根据患者的具体情况加以选择。     

重组卵泡刺激素与高纯度尿提取卵泡刺激素在辅助生殖的疗效比较

目的　比较重组卵泡刺激素 (rFSH)与高纯度尿提取卵泡刺激素 (uFSH)在促超排卵周期中的有效性和安全性。　方法　 2 0 2例接受体外受精 胚胎移植 (IVF ET)的不育患者 ,随机分为rFSH组 1 0 0例及uFSH组 1 0 2例。两组均采用黄体期长方案促超排卵。卵泡监测、取卵、IVF、ET等均按本中心常规进行。观察两组用药时间、用药剂量、获卵数、妊娠率及重度卵巢过度刺激综合征 (OHSS)发生率等。　结果　rFSH组与uF SH组比较 ,使用FSH天数及安瓿数显著减少 (P <0 .0 5) ,分别为 ( 1 2 .5± 2 .4)及 ( 1 4 .6±1 .7)、( 2 8.7± 7.6)及 ( 3 2 .6± 4.9) ,hCG日直径 >1 0mm的卵泡数、获卵数、优质胚胎率及可冻存胚胎率显著增多 (P <0 .0 5)。临床妊娠率 (分别为 42 %及 3 7.3 % )、胚胎种植率、多胎率、重度OHSS发生率 (分别为 3 %及 2 % )无显著差异 (P >0 .0 5)。　结论　虽然两组种植率及妊娠率无差异 ,但rFSH能更有效地促卵泡生长从而获得更多数量的优质卵与胚胎     

国产尿卵泡刺激素在体外受精-胚胎移植促排卵治疗中有效性的Meta分析

目的系统评价国产尿卵泡刺激素(uFSH)在体外受精-胚胎移植(IVF-ET)控制性促排卵治疗中的有效性。方法计算机检索VIP、CNKI和WanFang Data等数据库,查找比较uFSH与进口重组卵泡刺激素(rFSH)在IVF-ET促排卵治疗中半随机或随机对照试验(RCT)文献,并进行系统评价,采用RevMan 5.3软件进行Meta分析。结果 5篇RCT 903例患者满足纳入标准。结果显示:uFSH在促性腺激素(Gn)刺激天数[MD=0.45,95%CI(-0.42,1.31),P=0.31]、Gn用量[MD=3.37,95%CI(-0.19,6.93),P=0.06]、平均获卵数[MD=0.17,95%CI(-0.31,0.65),P=0.49]、HCG日雌二醇(E2)值[MD=-862.40,95%CI(-1858.03,133.23),P=0.09]、临床妊娠率[OR=1.02,95%CI(0.77,1.35),P=0.90]、流产率[OR=1.10,95%CI(0.54,2.26),P=0.79]、卵巢过度刺激综合征(OHSS)发生率[OR=1.03,95%CI(0.42,2.54),P=0.95]等方面与rFSH无明显差异,仅平均Gn费用[MD=-2.98,95%CI(-4.19,-1.77),P0.000 01]显著低于rFSH。结论 uFSH与rFSH相比,在Gn用量、平均获卵数、临床妊娠率等方面相当,但采用uFSH可减少促排卵治疗费用。     

基因重组/尿卵泡刺激素在体外受精-胚胎移植周期临床效果的比较

目的评估基因重组和尿卵泡刺激素在体外受精-胚胎移植(IVF-ET)周期中临床效果的差异。方法对单纯输卵管性因素行IVF-ET 90例患者,随机分为两组。分别给予尿卵泡刺激素(u-FSH)与基因重组卵泡刺激素(r-FSH)促排卵的结果进行比较。结果u-FSH组卵子成熟率显著高于r-FSH组(P<0.01),而平均费用、人绒毛膜促性腺激素(hCG)日血清雌二醇(E2)水平低于r-FSH组(P<0.05)。两组受精率、优质胚胎率、种植率、妊娠率、平均获卵率、促排卵天数、促性腺激素(Gn)用量、局部反应、内膜厚度差异无显著性(P>0.05)。结论在IVF-ET治疗周期中,u-FSH在不影响妊娠率的同时较r-FSH更有助于卵泡成熟,具有较大的价格优势,并有降低卵巢过度刺激综合征(OHSS)发生的趋势。因此,u-FSH有可能成为IVF-ET治疗周期中较为理想的促排卵药物。     

Anesthetic impact of body mass index in patients undergoing assisted reproductive technologies

STUDY OBJECTIVE: To determine the prevalence and anesthetic impact of obesity in patients undergoing assisted reproductive technologies. DESIGN: Retrospective analysis of a complete calendar year of oocyte retrieval procedures. SETTING: Center for reproductive medicine of a tertiary care university teaching hospital. PATIENTS: 1,289 ASA physical status I, II, and III women undergoing oocyte retrieval procedures. MEASUREMENTS: Patient demographics, body mass index (BMI), comorbid conditions, frequency and characterization of intraoperative and postoperative events, route of oocyte retrieval, and anesthetic technique were assessed. MAIN RESULTS: Of the 1,289 women, 33% were overweight or obese. The prevalence of gastroesophageal reflux disease, depression/anxiety, hypothyroidism, diabetes, and hypertension was associated with increasing BMI (P < 0.02). Transvaginal oocyte retrieval and the use of total intravenous anesthesia were less common with increasing BMI (P < 0.01; P < 0.003). Oxygen desaturation occurred more frequently intraoperatively and postoperatively in patients with high BMI (P < 0.0001), as did the reports of postoperative discomfort and the need for additional analgesia (P < 0.001). No patients managed with spinal anesthesia experienced intraoperative desaturation or required conversion to general anesthesia with endotracheal intubation. CONCLUSIONS: Patients with high BMI have a greater prevalence of comorbid conditions, require alterations in anesthetic and oocyte retrieval management, and more often experience intraoperative and postoperative events.     

右美托咪啶辅助表面麻醉用于患者支气管肺泡灌洗术的效果

Objective To investigate the efficacy of dexmedetomidine-assisted topical anesthesia in patients undergoing bronchoalveolar lavage ( BAL). Methods Twenty-four ASA Ⅱ or Ⅲ patients in ICU, aged 24-64 yr, weighing 50-80 kg, scheduled for BAL, were randomly divided into 2 groups ( n = 12 each) : topical anesthesia group (group A) , topical anesthesia + dexmedetomidine group (group B) . In group A, 0.9% normal saline 5 ml was injected intravenously 30 min before operation, 2% lidocaine 5-10 ml was given via a tracheal tube or cannula 5 min before operation and then an increment of 2% lidocaine 5 ml was given using fibreoptic bronchoscope every 15-30 min as required (the total amount was within 20 ml) . In group B, dexmedetomidine 0.5-1.0 μg/kg was injected (time of injection≥ 10 min) followed by infusion at 0.1-0.5 μg·kg-1 ·h-1 and the topical anesthesia was performed as the method described in group A. The time of lavage, adverse reactions and adverse cardiovascular events were recorded. Blood samples were taken 20 min before lavage, 20 min after the start of lavage and 20 min after the end of lavage (T1-3 ) for determination of the concentrations of plasma catecholamine and serum cortisol. Results The incidences of adverse reactions and adverse cardiovascular events were significantly lower and the operation time was significantly shorter in group B than in group A ( P < 0.05). The concentrations of plasma catecholamine and serum cortisol were significantly higher at T2,3 in group A, while lower at T2,3 in group B than at T1 ( P < 0.05) . The concentrations of plasma catecholamine and serum cortisol were significantly lower in group B than in group A ( P < 0.05). Conclusion Dexmedetomidine-assisted topical anesthesia can be used safely and effectively in BAL.     

右美托咪啶辅助表面麻醉用于患者支气管肺泡灌洗术的效果

目的 探讨右美托咪啶辅助表面麻醉用于患者支气管肺泡灌洗术的效果.方法 拟行支气管肺泡灌洗术的ICU患者24例,ASA分级Ⅱ或Ⅲ级,体重50～80 kg,年龄24～64岁,采用随机数字表法,将患者随机分为2组(n=12),A组术前30 min静脉注射0.9%生理盐水5 ml,术前5 min经气管导管或气管套管内注入2%利多卡因5～10 ml,随后按需每15～30 min经纤维支气管镜追加2%利多卡因5 ml,总量控制在20 ml以内;B组术前30 min缓慢静脉注射右美托咪啶0.5～1.0 μg/kg,随后以0.1～0.5 μg·kg-1·h-1速率维持,表面麻醉方法同A组.记录灌洗时间、不良反应及心血管不良事件的发生情况.于灌洗前20 min(T1)、灌洗开始后20 min(T2)、灌洗结束后20 min(T3)时采集血样,测定血浆儿茶酚胺浓度和血清皮质醇浓度.结果 与A组比较,B组血清皮质醇浓度、血浆儿茶酚胺浓度降低、不良反应及心血管不良事件发生率降低,操作时间缩短(P<0.05).与T1时比较,A组T2,3时血清皮质醇及血浆儿茶酚胺浓度升高,B组T2,3时血清皮质醇及血浆儿茶酚胺浓度降低(P<0.05).结论 右美托咪啶辅助表面麻醉可安全有效地用于患者支气管肺泡灌洗术.

Abstract：

Objective To investigate the efficacy of dexmedetomidine-assisted topical anesthesia in patients undergoing bronchoalveolar lavage ( BAL). Methods Twenty-four ASA Ⅱ or Ⅲ patients in ICU, aged 24-64 yr, weighing 50-80 kg, scheduled for BAL, were randomly divided into 2 groups ( n = 12 each) : topical anesthesia group (group A) , topical anesthesia + dexmedetomidine group (group B) . In group A, 0.9% normal saline 5 ml was injected intravenously 30 min before operation, 2% lidocaine 5-10 ml was given via a tracheal tube or cannula 5 min before operation and then an increment of 2% lidocaine 5 ml was given using fibreoptic bronchoscope every 15-30 min as required (the total amount was within 20 ml) . In group B, dexmedetomidine 0.5-1.0 μg/kg was injected (time of injection≥ 10 min) followed by infusion at 0.1-0.5 μg·kg-1 ·h-1 and the topical anesthesia was performed as the method described in group A. The time of lavage, adverse reactions and adverse cardiovascular events were recorded. Blood samples were taken 20 min before lavage, 20 min after the start of lavage and 20 min after the end of lavage (T1-3 ) for determination of the concentrations of plasma catecholamine and serum cortisol. Results The incidences of adverse reactions and adverse cardiovascular events were significantly lower and the operation time was significantly shorter in group B than in group A ( P < 0.05). The concentrations of plasma catecholamine and serum cortisol were significantly higher at T2,3 in group A, while lower at T2,3 in group B than at T1 ( P < 0.05) . The concentrations of plasma catecholamine and serum cortisol were significantly lower in group B than in group A ( P < 0.05). Conclusion Dexmedetomidine-assisted topical anesthesia can be used safely and effectively in BAL.     

右美托咪啶辅助表面麻醉用于患者支气管肺泡灌洗术的效果

Objective To investigate the efficacy of dexmedetomidine-assisted topical anesthesia in patients undergoing bronchoalveolar lavage ( BAL). Methods Twenty-four ASA Ⅱ or Ⅲ patients in ICU, aged 24-64 yr, weighing 50-80 kg, scheduled for BAL, were randomly divided into 2 groups ( n = 12 each) : topical anesthesia group (group A) , topical anesthesia + dexmedetomidine group (group B) . In group A, 0.9% normal saline 5 ml was injected intravenously 30 min before operation, 2% lidocaine 5-10 ml was given via a tracheal tube or cannula 5 min before operation and then an increment of 2% lidocaine 5 ml was given using fibreoptic bronchoscope every 15-30 min as required (the total amount was within 20 ml) . In group B, dexmedetomidine 0.5-1.0 μg/kg was injected (time of injection≥ 10 min) followed by infusion at 0.1-0.5 μg·kg-1 ·h-1 and the topical anesthesia was performed as the method described in group A. The time of lavage, adverse reactions and adverse cardiovascular events were recorded. Blood samples were taken 20 min before lavage, 20 min after the start of lavage and 20 min after the end of lavage (T1-3 ) for determination of the concentrations of plasma catecholamine and serum cortisol. Results The incidences of adverse reactions and adverse cardiovascular events were significantly lower and the operation time was significantly shorter in group B than in group A ( P < 0.05). The concentrations of plasma catecholamine and serum cortisol were significantly higher at T2,3 in group A, while lower at T2,3 in group B than at T1 ( P < 0.05) . The concentrations of plasma catecholamine and serum cortisol were significantly lower in group B than in group A ( P < 0.05). Conclusion Dexmedetomidine-assisted topical anesthesia can be used safely and effectively in BAL.     

Endometriosis of the urinary tract in women of reproductive age

AIM: We present our experience with diagnosing and treating 22 cases of urinary tract endometriosis in women of reproductive age. PATIENTS AND METHODS: From January 2001 to January 2003, 22 women of reproductive age (mean age 34.8 years) were diagnosed suffering from endometriosis of the urinary tract. We used the Endoscopic Endometriosis Classification (EEC) for assessing the stage of endometriosis. RESULTS: Endometriosis was present in the bladder, the lower third of the ureter, and in a postnephrectomy ureteral stump in 15 (68.1%), six (27.2%) and one (4.5%) cases, respectively. The EEC classification revealed stages I, II, III and IV in four (18.1%), one (4.5%), one (4.5%), and 16 (72.7%) patients, respectively. Urinary symptoms were present in 14 (63.6%) patients. For the treatment of bladder endometriosis, 10 patients underwent partial cystectomy, while the remaining five patients were treated with transurethral resection. In four patients ureterolysis was performed, by laparoscopy in two cases and by open surgery in the other two cases. Ureterectomy and re-implantation with bladder psoas hitching took place in six patients. In the case of endometriosis of the ureteral stump, open surgical excision took place. During the mean follow-up period of 20 months (range 16-40) no long-term complication or relapse was diagnosed. CONCLUSIONS: Bladder and ureteral endometriosis should be considered in women of reproductive age with non-specific urinary tract or abdominal symptoms, and surgical treatment is recommended.     

中国乙型肝炎和非肝炎男性间的精液质量和辅助生殖技术治疗结果的比较

本研究旨在确定乙型肝炎病毒（HBV）感染对精子质量和辅助生殖技术治疗结局的影响。分析2008年1月至2009年12月于浙江大学附属妇产科医院寻求辅助生育治疗的916例男性（457例乙型肝炎病毒携带者和459例阴性对照男性）的精液参数;将2004年1月至2009年12月期间的男性乙肝病毒携带的587个常规体外受精（In vitro fertilisation,IVF）周期和325个单精子卵细胞浆内注射（Intracytoplasmic sperm injection,ICSI）周期作为阳性观察组,根据取卵日期、女方年龄及ART受精方式通过统计软件以1：1比例匹配,设立夫妇双方均为HBsAg阴性的对照组（587个IVF周期,324个ICSI周期）,分析两组间的辅助生殖治疗结局。与对照组相比,乙肝携带者表现有较低的精液体积、精子总数以及较差的精子活动力和形态学表现（P〈0．05）;乙肝男性夫妇接受ICSI治疗后,双原核（2PN）受精率、优质胚胎率、胚胎着床率以及临床妊娠率均显著性降低俨〈0．05）;而两组病人间的IVF治疗结局差异无显著性（P〉0．05）。通过Logistic回归分析发现乙肝病毒感染作为一个独立的因素增加少弱精子症的发生以及降低ICSI治疗周期的胚胎着床率和临床妊娠率（P〈0．05）。我们的研究结果提示了男性乙型肝炎病毒感染与较差的精子质量和ICSI治疗结局有关,而对IVF治疗结局没有明显的影响。